Geron Corp GERN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights
-
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
-
Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024
-
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
-
Geron Shares Rise Premarket on FDA Nod for Rytelo
Trading Information
- Previous Close Price
- $4.31
- Day Range
- $4.27–4.39
- 52-Week Range
- $1.64–5.34
- Bid/Ask
- $4.31 / $4.34
- Market Cap
- $2.60 Bil
- Volume/Avg
- 5.0 Mil / 9.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,908.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 141
- Website
- https://www.geron.com
Comparables
Valuation
|
Metric
|
GERN
|
KROS
|
GILD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 17.94 |
Price/Book Value | 8.45 | 5.15 | 5.74 |
Price/Sales | 1,908.77 | 7,272.07 | 3.79 |
Price/Cash Flow | — | — | 9.11 |
Price/Earnings
GERN
KROS
GILD
Financial Strength
|
Metric
|
GERN
|
KROS
|
GILD
|
|---|---|---|---|
Quick Ratio | 3.53 | 19.17 | 0.69 |
Current Ratio | 3.61 | 20.37 | 1.14 |
Interest Coverage | −20.43 | — | 2.58 |
Quick Ratio
GERN
KROS
GILD
Profitability
|
Metric
|
GERN
|
KROS
|
GILD
|
|---|---|---|---|
Return on Assets (Normalized) | −44.04% | −33.90% | 9.97% |
Return on Equity (Normalized) | −63.72% | −36.95% | 28.96% |
Return on Invested Capital (Normalized) | −53.15% | −35.57% | 14.56% |
Return on Assets
GERN
KROS
GILD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kjmsffmhc | Blz | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zfzxwpz | Jwxxfs | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dqwfrzcx | Zwgmzm | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nkvbsfh | Jcmpj | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Vwbplvdn | Jnv | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Jlykzsyz | Vqqq | $28.5 Bil | |||
| Moderna Inc
MRNA
| Ndjdgvyl | Npqd | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Zqxgqyvbz | Trbs | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pgmypdtfh | Kykyy | $13.0 Bil | |||
| Incyte Corp
INCY
| Kmkhpxgnc | Tmvskr | $12.9 Bil |
United States